---
title: "This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293338058.md"
description: "Top Wall Street analysts initiated coverage on five stocks with bullish outlooks. BMO Capital's Connor Mackay rated Insmed (INSM) Outperform with a $192 price target, while Malcolm Hoffman rated Axsome Therapeutics (AXSM) Outperform with a $310 target. Compass Point's Rob Simone gave American Healthcare REIT (AHR) a Buy rating at $70. BMO's Connor Murphy rated Trevi Therapeutics (TRVI) Outperform at $36, and Rodman & Renshaw's Seema Sheoran rated Eledon Pharmaceuticals (ELDN) Buy at $12."
datetime: "2026-07-21T11:58:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293338058.md)
  - [en](https://longbridge.com/en/news/293338058.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293338058.md)
generator: "portal-rs"
---

# This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   BMO Capital analyst Connor Mackay initiated coverage on **Insmed Inc** (NASDAQ:INSM) with an Outperform rating and announced a price target of $192. Insmed shares closed at $107.02 on Monday. See how other analysts view this stock.
-   BMO Capital analyst Malcolm Hoffman initiated coverage on **Axsome Therapeutics Inc** (NASDAQ:AXSM) with an Outperform rating and announced a price target of $310. Axsome Therapeutics shares closed at $221.64 on Monday. See how other analysts view this stock.
-   Compass Point analyst Rob Simone initiated coverage on **American Healthcare REIT Inc** (NYSE:AHR) with a Buy rating and announced a price target of $70. American Healthcare shares closed at $56.66 on Monday. See how other analysts view this stock.
-   BMO Capital analyst Connor Murphy initiated coverage on **Trevi Therapeutics Inc** (NASDAQ:TRVI) with an Outperform rating and announced a price target of $36. Trevi Therapeutics shares closed at $16.77 on Tuesday. See how other analysts view this stock.
-   Rodman & Renshaw analyst Seema Sheoran initiated coverage on **Eledon Pharmaceuticals Inc** (NASDAQ:ELDN) with a Buy rating and announced a price target of $12. Eledon Pharmaceuticals shares closed at $3.86 on Monday. See how other analysts view this stock.

Considering buying INSM stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [ELDN.US](https://longbridge.com/en/quote/ELDN.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [AXSM.US](https://longbridge.com/en/quote/AXSM.US.md)
- [AHR.US](https://longbridge.com/en/quote/AHR.US.md)

## Related News & Research

- [Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts](https://longbridge.com/en/news/296880224.md)
- [Great Lakes Advisors LLC Invests $1.65 Million in Axsome Therapeutics, Inc. $AXSM](https://longbridge.com/en/news/296676631.md)
- [Insmed says Japan health ministry approves BRINSUPRI for non-cystic fibrosis bronchiectasis](https://longbridge.com/en/news/296776774.md)
- [American Healthcare REIT enters forward sale agreements tied to 1,987,500-share follow-on option exercise](https://longbridge.com/en/news/296825162.md)
- [Insmed director Melvin Sharoky, M.D. sells 5,000 shares for $637,650](https://longbridge.com/en/news/296395374.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**